Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases

October 30, 2018 | City of Hope

City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.

Four symptoms not to ignore if you’ve had cancer

January 23, 2018 | Denise Heady

Neurosurgeon and scientist Rahul Jandial says some symptoms should never be ignored by former cancer patients. More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools.

Cancer insights: Cancer patients are superhuman

June 5, 2017 | Rahul Jandial, M.D., Ph.D.

In the past seven years at City of Hope, I’ve had the privilege of providing care for many patients with cancer. Quite simply, they are the real superhumans. Please allow me to offer four examples for your consideration, from my personal insight.

Wolf in sheep's clothing: breast cancer cloaks itself in brain proteins to invade the brain

March 14, 2017 | Denise Heady

More women than ever are surviving breast cancer only to die of secondary brain tumors years after they’ve been declared cancer-free. This is particularly true for patients with the breast cancer subtype HER2-positive. Now City of Hope researchers have discovered how this happens.

June Grad Student Forum: Cecilia Choy

July 9, 2014 | Cecilia Choy

Cooperation of Neurotrophin Receptor TrkB and Her2 in Breast Cancer Cells Facilitates Brain Metastasis Cecilia Choy, Josh Neman, Matthew Duenas, Hubert Li, Nagarajan Vaidehi, Rahul Jandial Metastases are responsible for 90% of all cancer deaths, and patients diagnosed with brain metastasis have a dismal 20% probability of one-year survival.